Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data

William V Bobo, Jeffrey A. Stovall, Molly Knostman, Jim Koestner, Richard C. Shelton

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose. The effectiveness and tolerability of switching patients' therapy from brandname to generic clozapine are reviewed. Summary. Clozapine is the most effective treatment for patients with refractory psychotic disorders and is also effective for reducing suicidal and violent behavior in this same population. Generic versions of clozapine are widely used. However, possible differences in pharmacokinetic profiles between branded and generic clozapine, and the potential risks of medication changes in severely ill but stable patients, may result in apprehension about converting from branded to generic clozapine. Articles, abstracts, and clinical presentations that compared clinical outcomes between Clozaril (Novartis Pharmaceuticals, East Hanover, NJ) and generic forms of clozapine in patients with primary psychotic disorders, bipolar disorder, or related conditions were identified via a computerized search of the medical literature. Thirteen relevant reports, mostly uncontrolled observational studies or chart reviews, described the effects of switching from brand-name to generic clozapine in 966 patients. The majority of patients tolerated conversion without worsening of symptoms or adverse effects, increased intensive service utilization, or medication adjustment. Clinical deterioration was described in a case review and in one randomized, controlled study. Conclusion. Available literature supports the effectiveness and safety of generic clozapine formulations in patients who previously were stable during treatment with brand-name clozapine. The risk of poor outcome after conversion to a generic clozapine formulation appears to be low but difficult to predict. Patients should be closely monitored during the first one to three months after conversion from one formulation to another.

Original languageEnglish (US)
Pages (from-to)27-37
Number of pages11
JournalAmerican Journal of Health-System Pharmacy
Volume67
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Clozapine
Names
Psychotic Disorders
Social Adjustment
Observational Studies
Therapeutics
Pharmacokinetics
Safety

Keywords

  • Antipsychotic agents
  • Clozapine
  • Drugs
  • Mental disorders
  • Pharmacokinetics
  • Substitution
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Converting from brand-name to generic clozapine : A review of effectiveness and tolerability data. / Bobo, William V; Stovall, Jeffrey A.; Knostman, Molly; Koestner, Jim; Shelton, Richard C.

In: American Journal of Health-System Pharmacy, Vol. 67, No. 1, 01.01.2010, p. 27-37.

Research output: Contribution to journalArticle

Bobo, William V ; Stovall, Jeffrey A. ; Knostman, Molly ; Koestner, Jim ; Shelton, Richard C. / Converting from brand-name to generic clozapine : A review of effectiveness and tolerability data. In: American Journal of Health-System Pharmacy. 2010 ; Vol. 67, No. 1. pp. 27-37.
@article{69bcb1877c6f4a429f2312d30f8acb83,
title = "Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data",
abstract = "Purpose. The effectiveness and tolerability of switching patients' therapy from brandname to generic clozapine are reviewed. Summary. Clozapine is the most effective treatment for patients with refractory psychotic disorders and is also effective for reducing suicidal and violent behavior in this same population. Generic versions of clozapine are widely used. However, possible differences in pharmacokinetic profiles between branded and generic clozapine, and the potential risks of medication changes in severely ill but stable patients, may result in apprehension about converting from branded to generic clozapine. Articles, abstracts, and clinical presentations that compared clinical outcomes between Clozaril (Novartis Pharmaceuticals, East Hanover, NJ) and generic forms of clozapine in patients with primary psychotic disorders, bipolar disorder, or related conditions were identified via a computerized search of the medical literature. Thirteen relevant reports, mostly uncontrolled observational studies or chart reviews, described the effects of switching from brand-name to generic clozapine in 966 patients. The majority of patients tolerated conversion without worsening of symptoms or adverse effects, increased intensive service utilization, or medication adjustment. Clinical deterioration was described in a case review and in one randomized, controlled study. Conclusion. Available literature supports the effectiveness and safety of generic clozapine formulations in patients who previously were stable during treatment with brand-name clozapine. The risk of poor outcome after conversion to a generic clozapine formulation appears to be low but difficult to predict. Patients should be closely monitored during the first one to three months after conversion from one formulation to another.",
keywords = "Antipsychotic agents, Clozapine, Drugs, Mental disorders, Pharmacokinetics, Substitution, Toxicity",
author = "Bobo, {William V} and Stovall, {Jeffrey A.} and Molly Knostman and Jim Koestner and Shelton, {Richard C.}",
year = "2010",
month = "1",
day = "1",
doi = "10.2146/ajhp080595",
language = "English (US)",
volume = "67",
pages = "27--37",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "1",

}

TY - JOUR

T1 - Converting from brand-name to generic clozapine

T2 - A review of effectiveness and tolerability data

AU - Bobo, William V

AU - Stovall, Jeffrey A.

AU - Knostman, Molly

AU - Koestner, Jim

AU - Shelton, Richard C.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Purpose. The effectiveness and tolerability of switching patients' therapy from brandname to generic clozapine are reviewed. Summary. Clozapine is the most effective treatment for patients with refractory psychotic disorders and is also effective for reducing suicidal and violent behavior in this same population. Generic versions of clozapine are widely used. However, possible differences in pharmacokinetic profiles between branded and generic clozapine, and the potential risks of medication changes in severely ill but stable patients, may result in apprehension about converting from branded to generic clozapine. Articles, abstracts, and clinical presentations that compared clinical outcomes between Clozaril (Novartis Pharmaceuticals, East Hanover, NJ) and generic forms of clozapine in patients with primary psychotic disorders, bipolar disorder, or related conditions were identified via a computerized search of the medical literature. Thirteen relevant reports, mostly uncontrolled observational studies or chart reviews, described the effects of switching from brand-name to generic clozapine in 966 patients. The majority of patients tolerated conversion without worsening of symptoms or adverse effects, increased intensive service utilization, or medication adjustment. Clinical deterioration was described in a case review and in one randomized, controlled study. Conclusion. Available literature supports the effectiveness and safety of generic clozapine formulations in patients who previously were stable during treatment with brand-name clozapine. The risk of poor outcome after conversion to a generic clozapine formulation appears to be low but difficult to predict. Patients should be closely monitored during the first one to three months after conversion from one formulation to another.

AB - Purpose. The effectiveness and tolerability of switching patients' therapy from brandname to generic clozapine are reviewed. Summary. Clozapine is the most effective treatment for patients with refractory psychotic disorders and is also effective for reducing suicidal and violent behavior in this same population. Generic versions of clozapine are widely used. However, possible differences in pharmacokinetic profiles between branded and generic clozapine, and the potential risks of medication changes in severely ill but stable patients, may result in apprehension about converting from branded to generic clozapine. Articles, abstracts, and clinical presentations that compared clinical outcomes between Clozaril (Novartis Pharmaceuticals, East Hanover, NJ) and generic forms of clozapine in patients with primary psychotic disorders, bipolar disorder, or related conditions were identified via a computerized search of the medical literature. Thirteen relevant reports, mostly uncontrolled observational studies or chart reviews, described the effects of switching from brand-name to generic clozapine in 966 patients. The majority of patients tolerated conversion without worsening of symptoms or adverse effects, increased intensive service utilization, or medication adjustment. Clinical deterioration was described in a case review and in one randomized, controlled study. Conclusion. Available literature supports the effectiveness and safety of generic clozapine formulations in patients who previously were stable during treatment with brand-name clozapine. The risk of poor outcome after conversion to a generic clozapine formulation appears to be low but difficult to predict. Patients should be closely monitored during the first one to three months after conversion from one formulation to another.

KW - Antipsychotic agents

KW - Clozapine

KW - Drugs

KW - Mental disorders

KW - Pharmacokinetics

KW - Substitution

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=74049124895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049124895&partnerID=8YFLogxK

U2 - 10.2146/ajhp080595

DO - 10.2146/ajhp080595

M3 - Article

C2 - 20044366

AN - SCOPUS:74049124895

VL - 67

SP - 27

EP - 37

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 1

ER -